This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Special Measures Agreement (SMA) | |
|---|---|
| Name | Special Measures Agreement |
| Type | Regulatory compliance agreement |
| Jurisdiction | International and national regulatory bodies |
| Established | Variable (used in 20th–21st centuries) |
| Related | Consent decree; Deferred Prosecution Agreement; Memorandum of Understanding |
Special Measures Agreement (SMA) A Special Measures Agreement (SMA) is a formal compliance instrument used by regulatory bodies, enforcement agencies, and oversight institutions to require remedial action from entities found deficient in statutory, contractual, or licensing obligations. Originating in administrative enforcement practice, SMAs are deployed in contexts ranging from financial supervision and healthcare oversight to broadcasting regulation and defense contracting. They function as structured, time-bound accords that combine specific corrective measures, reporting obligations, and supervision protocols to mitigate risks, protect public interests, and restore conformity with applicable standards.
SMAs trace intellectual and practical roots to instruments such as the Consent decree, Deferred Prosecution Agreement, and Memorandum of Understanding used by bodies including the United States Department of Justice, Securities and Exchange Commission, Federal Communications Commission, and Care Quality Commission. The purpose is to address systemic failures without immediate revocation of licenses or wholesale dissolution of organizations—balancing regulatory remediation with continuity of services. SMAs are intended to remediate issues similar to those confronted in notable regulatory episodes involving Lehman Brothers, Barclays, Toyota, Bank of America, and GlaxoSmithKline, where targeted oversight and binding commitments were used to correct corporate conduct.
SMAs operate within statutory and administrative law frameworks such as statutes enforced by the Financial Conduct Authority, European Commission, Australian Securities and Investments Commission, National Health Service, and national ministries including the United States Department of Health and Human Services and the Ministry of Justice (United Kingdom). They often sit alongside instruments like the Administrative Procedure Act and international regimes such as Basel Accords and World Health Organization guidelines. Authority to impose an SMA derives from licensing statutes, regulatory orders, or settlement powers exemplified by actions under the Securities Exchange Act of 1934, Bank Holding Company Act, or sector-specific statutes like the Health and Social Care Act 2012.
Regulators typically issue SMAs after inspections, audits, enforcement investigations, or incidents akin to failures reviewed in inquiries such as the Leveson Inquiry, Francis Report, and Financial Crisis Inquiry Commission. Criteria include evidence of systemic noncompliance, risks to consumers or patients, repeated violations seen in cases like Enron or Theranos, and situations where suspension of services would cause disproportionate harm as occurred in Ryanair operational disputes or NHS provider failures. The process generally follows stages mirrored in administrative actions: notice of concerns, provisional measures, negotiation with entities represented by counsel from firms like Freshfields, Linklaters, or Skadden, Arps, execution of the SMA, and public disclosure consistent with practice in matters involving the Department of Justice and Office of the Comptroller of the Currency.
Typical SMA provisions echo compliance mandates from settlements involving JPMorgan Chase, Wells Fargo, and BP, and can include governance restructuring, appointment of independent monitors similar to those used after the Volkswagen emissions scandal, enhancement of internal controls modeled on Sarbanes–Oxley Act compliance, mandatory training programs akin to those in GlaxoSmithKline settlements, and restitution or remediation obligations comparable to remedies in Deepwater Horizon responses. Obligations frequently require submission of compliance plans, implementation timelines, board-level oversight, appointment of a chief compliance officer, and enhanced reporting to regulators such as the Financial Conduct Authority, Food and Drug Administration, European Medicines Agency, or National Audit Office.
Monitoring mechanisms in SMAs often employ independent third-party monitors, audit regimes, and periodic attestations, analogous to oversight in cases overseen by the Independent Monitoring Board or monitors appointed under consent decrees with the Department of Justice. Enforcement tools include escalation protocols, fines similar to sanctions by the European Central Bank and Federal Reserve System, suspension of privileges, referral to criminal prosecutors like the Crown Prosecution Service, or conversion to more intrusive remedies such as revocation of licenses exemplified by actions against Radio Authority licensees. Termination occurs upon fulfillment of milestones, expiry of terms, or regulatory determination of sustained compliance; termination reviews may draw on methodologies from the Public Accounts Committee or international peer review mechanisms.
SMAs aim to remediate harm, restore confidence, and impose structural change without immediate dissolution, outcomes observed in post-agreement recoveries of firms like Barclays and General Motors after crisis interventions. Measured impacts include reductions in recurrence of violations, improvements in audit findings comparable to post-Sarbanes–Oxley effects, and enhanced consumer protections noted in health sector recoveries after Francis Report driven interventions. Criticisms mirror debates over Deferred Prosecution Agreements and Consent decrees, focusing on perceptions of regulatory capture, adequacy of sanctions, and sufficiency of independent monitoring as debated in inquiries involving Wells Fargo and Volkswagen.
Notable applications of SMA-like instruments include remediation agreements following the Deepwater Horizon spill response, compliance settlements with GlaxoSmithKline and Siemens, supervisory measures in banking after the 2007–2008 financial crisis, and sectoral interventions in healthcare referenced in the Francis Report concerning Mid Staffordshire NHS Foundation Trust. Regulatory examples include actions by the Federal Communications Commission in broadcasting compliance, interventions by the Care Quality Commission in provider oversight, and supervisory measures by the European Central Bank and Bank of England addressing systemic banking weaknesses.
Category:Regulatory agreements